Therapeutic targets in polycystic liver disease

Current Drug Targets

Volumn 18, Issue 8, 2017, Pages 950-957

  Masyuk, Tatyana V ^a   Masyuk, Anatoliy I ^a   Larusso, Nicholas F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholangiociliopathies; Cholangiocytes; Cilia; Hepatic cystogenesis; Polycystic liver disease; Therapies

Indexed keywords

ANGIOPEPTIN; BOSUTINIB; CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; EVEROLIMUS; FIBROCYSTIN; FOLLITROPIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; HISTONE DEACETYLASE 6; MAMMALIAN TARGET OF RAPAMYCIN; MARIMASTAT; MENADIONE; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; OCTREOTIDE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN KINASE P60; RAPAMYCIN; RICOLINOSTAT; SECRETIN; SEMAXANIB; SOMATOSTATIN RECEPTOR; SORAFENIB; TELMISARTAN; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VANILLOID RECEPTOR 4; SOMATOSTATIN;

AUTOPHAGY; BINDING AFFINITY; CALCIUM CELL LEVEL; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLANGIOCYTE; CILIOPATHY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; LIVER POLYCYSTIC DISEASE; MAINTENANCE THERAPY; NONHUMAN; PRIMARY CILIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; CYST; DRUG EFFECTS; GENE REGULATORY NETWORK; LIVER DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; PRECLINICAL STUDY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYSTS; DRUG EVALUATION, PRECLINICAL; GENE REGULATORY NETWORKS; HUMANS; LIVER DISEASES; MOLECULAR TARGETED THERAPY; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 85020396242     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150427161743     Document Type: Review

References (71)

1. Perugorria MJ, Masyuk TV, Marin, et al. Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol 2014; 11(12): 750-61.
2. Masyuk T, Masyuk A, Larusso N. Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol 2009; 23(3): 265-71.
3. Cnossen WR, Drenth JP. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis 2014; 9: 69.
4. Strazzabosco M, Somlo S. Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology 2011; 140(7): 1855-9.
5. Wills ES, Roepman R, Drenth JP. Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol Med 2014; 20(5): 261-70.
6. Masyuk AI, Gradilone SA, LaRusso NF. Calcium signaling in cilia and ciliary-mediated intracellular calcium signaling: are they independent or coordinated molecular events? Hepatology 2014; 60(5): 1783-5.
7. Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008; 237(8): 2007-12.
8. Braun WE. Advances in autosomal dominant polycystic kidney disease-2014 and beyond. Cleve Clin J Med 2014; 81(9): 545-56.
9. Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 2014; 124(6): 2315-24.
10. Temmerman F, Missiaen L, Bammens B, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharmacol Ther 2011; 34(7): 702-13.
11. Paul BM, Vanden Heuvel GB. Kidney: polycystic kidney disease. Wiley Interdiscip Rev Dev Biol 2014; 3(6): 465-87.
12. Yoshihara D, Kugita M, Sasaki M, et al. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. PLoS One 2013; 8(12): e81480.
13. Janssen MJ, Waanders E, Te Morsche RH, et al. Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology 2011; 141(6): 2056-63.
14. Janssen MJ, Salomon J, Te Morsche RH, Drenth JP. Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease. PLoS One 2012; 7(11): e50324.
15. Cnossen WR, te Morsche RH, Hoischen A, et al. Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis. Proc Natl Acad Sci, USA 2014; 111(14): 5343-8.
16. Abu-Wasel B, Walsh C, Keough V, Molinari M. Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. W J Gastroenterol 2013; 19(35): 5775-86.
17. Everson GT, Helmke SM. Somatostatin, estrogen, and polycystic liver disease. Gastroenterology 2013; 145(2): 279-82.
18. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21(6): 1052-61.
19. Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int 2014; 35(5): 1607-14.
20. Masyuk TV, Huang BQ, Ward CJ, et al. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 2003; 125(5): 1303-10.
21. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007; 132(3): 1104-16.
22. Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009; 49(1): 160-74.
23. Masyuk TV, Radtke BN, Stroope AJ, et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 2012; 142(3): 622-33.
24. Banales JM, Masyuk TV, Bogert PS, et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173(6): 1637-46.
25. Alvaro D, Gigliozzi A, Attili AF. Regulation and deregulation of cholangiocyte proliferation. J Hepatol 2000; 33(2): 333-40.
26. Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. JASN 2014; 25(1): 18-32.
27. Masyuk TV, Radtke BN, Stroope AJ, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013; 58(1): 409-21.
28. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5(5): 783-9.
29. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137(5): 1661-8.
30. Temmerman F, Gevers T, Ho TA, et al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data. Aliment Pharmacol Ther 2013; 38(4): 397-406.
31. Chrispijn M, Nevens F, Gevers TJ, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35(2): 266-74.
32. Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27(9): 3532-9.
33. Afroze S, Meng F, Jensen K, et al. The physiological roles of secretin and its receptor. Ann Transl Med 2013; 1(3): 29.
34. Everson GT, Emmett M, Brown WR, Redmond P, Thickman D. Functional similarities of hepatic cystic and biliary epithelium: studies of fluid constituents and in vivo secretion in response to secretin. Hepatology 1990; 11(4): 557-65.
35. Wang X, Ye H, Ward CJ, et al. Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Am J Physiol Renal Physiol 2012; 303(7): F1089-98.
36. Mancinelli R, Onori P, Gaudio E, et al. Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1. Am J Physiol Gastrointest Liver Physiol 2009; 297(1): G11-26.
37. Onori P, Mancinelli R, Franchitto A, et al. Role of folliclestimulating hormone on biliary cyst growth in autosomal dominant polycystic kidney disease. Liver Int 2013; 33(6): 914-25.
38. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11(1): 55-67.
39. Keitel V, Haussinger D. TGR5 in cholangiocytes. Cur Opin Gastroenterol 2013; 29(3): 299-304.
40. Duboc H, Tache Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 2014; 46(4): 302-12.
41. Masyuk AI, Huang BQ, Radtke BN, et al. Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol 2013; 304(11): G1013-24.
42. Masyuk AI, Masyuk TV, Splinter PL, Huang BQ, Stroope AJ, LaRusso NF. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131(3): 911-20.
43. Masyuk TV, Lee SO, Radtke BN, et al. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. Am J Pathol 2014; 184(1): 110-21.
44. Spirli C, Morell CM, Locatelli L, et al. Cyclic AMP/PKAdependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology 2012; 56(6): 2363-74.
45. Spirli C, Okolicsanyi S, Fiorotto R, et al. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology 2010; 138(1): 360-71 e7.
46. Spirli C, Okolicsanyi S, Fiorotto R, et al. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology 2010; 51(5): 1778-88.
47. Gradilone SA, Masyuk AI, Splinter PL, et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc Natl Acad Sci USA 2007; 104(48): 19138-43.
48. Masyuk TV, Huang BQ, Masyuk AI, et al. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am J Pathol 2004; 165(5): 1719-30.
49. Kathem SH, Mohieldin AM, Abdul-Majeed S, et al. Ciliotherapy: a novel intervention in polycystic kidney disease. J Geriatr Cardiol 2014; 11(1): 63-73.
50. Gradilone SA, Masyuk TV, Huang BQ, et al. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology 2010; 139(1): 304-14 e2.
51. Gao H, Wang Y, Wegierski T, et al. PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum Mol Gen 2010; 19(1): 16-24.
52. 2+ signaling. Biochem Biophys Res Commun 2005; 338(2): 880-9.
53. Wang S, Zhang J, Nauli SM, et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 2007; 27(8): 3241-52.
54. Gradilone SA, Habringer S, Masyuk TV, Howard BN, Masyuk AI, Larusso NF. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol 2014; 184(3): 600-8.
55. Alvaro D, Mancino MG, Onori P, et al. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 2006; 12(22): 3537-45.
56. Urribarri AD, Munoz-Garrido P, Perugorria MJ, et al. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut 2014; 63(10): 1658-67.
57. Sweeney WE, Jr., von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008; 19(7): 1331-41.
58. Wuthrich RP, Mei C. Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother 2014; 15(8): 1085-95.
59. Alvaro D, Onori P, Alpini G, et al. Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol 2008; 172(2): 321-32.
60. Fabris L, Cadamuro M, Fiorotto R, et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006; 43(5): 1001-12.
61. Renken C, Fischer DC, Kundt G, Gretz N, Haffner D. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant 2011; 26(1): 92-100.
62. Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19(3): 631-8.
63. Gevers TJ, Drenth JP. Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol 2011; 27(3): 294-300.
64. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 2007; 293(1): C419-28.
65. Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 2011; 300(2): F465-74.
66. Lee SO, Masyuk T, Splinter P, et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118(11): 3714-24.
67. O'Hara SP, Gradilone SA, Masyuk TV, Tabibian JH, LaRusso NF. MicroRNAs in Cholangiopathies. Curr Pathobiol Rep 2014; 2(3): 133-42.
68. Masyuk T, Masyuk A, LaRusso N. MicroRNAs in cholangiociliopathies. Cell Cycle 2009; 8(9): 1324-8.
69. Komatsu M. Liver autophagy: physiology and pathology. J Biochem 2012; 152(1): 5-15.
70. Yang J, Zhao Y, Ma K, et al. Deficiency of hepatocystin induces autophagy through an mTOR-dependent pathway. Autophagy 2011; 7(7): 748-59.
71. Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol 2013; 59(1): 153-9.